Sh­iono­gi touts topline da­ta for Covid-19 an­tivi­ral for post-ex­po­sure treat­ment

Sh­iono­gi’s once-dai­ly 3CL pro­tease in­hibitor hit on a pri­ma­ry end­point in a late-stage tri­al as a post-ex­po­sure pro­phy­lax­is treat­ment for Covid-19 af­ter fail­ing a Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER